Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.00
Bid: 51.00
Ask: 53.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.922%)
Open: 52.50
High: 52.50
Low: 52.00
Prev. Close: 52.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

26 Sep 2019 12:15

RNS Number : 8173N
Cambridge Cognition Holdings PLC
26 September 2019
 

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Director/PDMR Shareholding

 

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 24 September 2019, Matthew Stork, Chief Executive Officer of the Company, purchased a total of 50,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 28.5 pence per Ordinary Share.

 

Following the transaction, Mr Stork has a total beneficial interest of 50,000 Ordinary Shares representing approximately 0.2% of the Company's issued share capital.

 

The notification below, made in accordance with the Market Abuse Regulation, provides further details in relation to the transaction.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

Tel: 01223 810 700

Matthew Stork, Chief Executive Officer

press@camcog.com

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Joint Broker)

Tel: 020 7220 0500

Geoff Nash/ Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney/ James Serjeant

IFC Advisory Ltd (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

The information below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Matthew Stork

2.

Reason for the Notification

a)

Position/status

PDMR - Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each

Identification code

GB00B8DV9647

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

28.5p

50,000

d)

Aggregated information:

·; Aggregated volume

·; Price

Purchase of a total of 50,000 ordinary shares at a price of 28.5p per ordinary share

e)

Date of the transaction

24 September 2019

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFQLFLKKFBBBZ
Date   Source Headline
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.